Caring for a Loved One with CCA: A Son’s Perspective

June/July 2022, Vol 3, No 2

At the 2022 Cholangiocarcinoma Foundation annual meeting, Ambuj Srivastava shared his experience as a current caregiver for his dad who was diagnosed with stage 2 extrahepatic cholangiocarcinoma (CCA). Ambuj lives in Toronto, Canada, with his wife, daughter, and parents. He is a mentee and patient advocate with the Cholangiocarcinoma Foundation.

Following a diagnosis of stage 2 extrahepatic CCA in September 2019, Ambuj’s father underwent surgery, chemotherapy, and immunotherapy. During that time, he “dealt with many monthly ER visits to the hospital due to blockages or infections.”

Ambuj described the initial days following his father’s diagnosis. “I was multitasking at work and home, talking to multiple specialists, coordinating meetings. There was a whole lot of information to process, stress, anxiety, confusion—it all became quite challenging,” Ambuj said. “We went through a rollercoaster of emotions. It was difficult and caused many restless nights.”

According to Ambuj, the caregiver role is a dynamic one, encompassing caregiving, care living, and care loving:

  • Caregiving is “a privilege for providing or taking care of a loved one during their most precious and maybe limited moments.”
  • Care living is “changing lifestyle, expectations, and boundaries for what you can and cannot do.”
  • Care loving is “self-care, which is usually given the least priority, but it is the glue that will keep you and your responsibilities together with a good support system in place.”

The biggest role is to advocate for the needs of the loved one, according to Ambuj. “It’s important to ensure that your loved one feels like they are in control of their health decisions,” he said. “Empower them to speak up and voice their concerns.”

Ambuj shared some pearls of wisdom that have helped him navigate his caregiving journey:

  • Define limits. Caregiving is a priority and balancing act that can become challenging. His advice: Plan for 1 day at a time.
  • Create a support system. This could include family, friends, support groups, managers, coworkers, mentors, social workers, and palliative support personnel—anyone who can provide physical and emotional assistance. Palliative support is important and does not necessarily mean the end of the road; it can provide many benefits to patients and their families.
  • Avoid caregiver burnout by assessing and managing with an appropriate support system.
  • Adopt the right mindset because “the first line of treatment is attitude.”

Ambuj recounted how his initial thinking about caregiving changed drastically after this experience. “I thought it was something that you would do for your loved one without any titles or any expressions or words,” he said. “But I now understand the importance of verbalizing and acknowledging the role of a caregiver.”

Ambuj concluded by saying, “Caregivers are like sidekicks to the real superheroes of this journey, Robin to the Batman. Superheroes are cool but I think sidekicks are pretty badass, too.”

Related Items

Importance of Proper Nutrition in Patients With Cholangiocarcinoma
June 2023, Vol 4, No 2
A specialist in oncology nutrition and the caregiver of a patient with cholangiocarcinoma discuss the importance of proper nutrition in achieving positive cancer outcomes.
Physician Debate: Is Chemotherapy Still the Backbone for CCA Treatment?
June 2023, Vol 4, No 2
Dr Rachna Shroff and Dr Madhulika Eluri debated whether it is time to move away from chemotherapy as a mainstay in the treatment of cholangiocarcinoma.
Incorporating ctDNA Into Clinical Trial Design
June 2023, Vol 4, No 2
Cholangiocarcinoma experts discussed potential applications of liquid biopsies using circulating tumor DNA.
Harnessing the Microbiome to Optimize Response to Immunotherapy
June 2023, Vol 4, No 2
Dr Marina Barcena-Varela described a study that aims to understand how the microbiome affects cholangiocarcinoma tumorigenesis based on genetic alterations and response to targeted and immunotherapy.
New Treatment Strategy for FGFR2 Fusion–Positive CCA
June 2023, Vol 4, No 2
Dr Michael E. Lidsky described a novel investigative murine model of FGFR2 fusion–positive intrahepatic cholangiocarcinoma and how it may enhance treatment outcomes.
CDX-1140 Plus Capecitabine, Oxaliplatin, and Pembrolizumab in Advanced BTC
June 2023, Vol 4, No 2
Dr Cecilia Monge presented the rationale and study design for a new phase 2 study investigating the CD40 agonist CDX-1140 in combination with capecitabine, oxaliplatin, and pembrolizumab in advanced biliary tract cancer.
Emerging Therapeutic Targets for CCA From Translational Research
June 2023, Vol 4, No 2
Dr Tim F. Greten discussed emerging targets for the treatment of cholangiocarcinoma coming from translational research studies.
Advances in CAR T-Cell Therapy in CCA
June 2023, Vol 4, No 2
Dr Mark O’Hara discussed the growing potential of CAR T-cell therapy in cholangiocarcinoma.
The Future of Clinical Trial Design in CCA Informed by Past Experiences
June 2023, Vol 4, No 2
Dr Sandra J. Casak discussed future thinking regarding clinical trials in cholangiocarcinoma, including a “seamless” oncology drug development paradigm.
Hot Topics on Cholangiocarcinoma at the 2023 Cholangiocarcinoma Foundation Annual Conference
By Melinda Bachini; Juan W. Valle, MB ChB, MSc, FRCP
Videos
On April 14, 2023, we presented an overview of key abstracts on cholangiocarcinoma (CCA) presented at the 2023 Cholangiocarcinoma Foundation Annual Conference.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: